This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ampio Blames Shorts But Won't Answer Legitimate Questions About Its Drugs

GREENWOOD VILLAGE, Col. ( TheStreet) -- Instead of addressing questions about its drug-development plans posed by critics, Ampio Pharmaceuticals (AMPE - Get Report) blames short sellers for trying to destroy the company.

On Friday, Ampio Chairman and CEO Mike Macaluso accused Seeking Alpha contributor Joe Dredly of trying to intentionally "damage the existing shareholders by triggering a downward pressure on their stock holdings."

In his statement, Macaluso also links Dredly with Peter Bortel, a hedge fund manager who wrote a series of negative articles about Ampio in 2011. While writing about Ampio, Bortel was also "working with a group of short selling speculators" and under investigation and a cease-and-desist order from the Securities and Exchange Commission, Macaluso claims.

This all sounds very sinister, which is what Macaluso wants investors to believe. In reality, Ampio's response is just a lazy, diversionary tactic. By attacking the credibility of its critics, the company hopes investors won't realize or care that responses to legitimate questions remain unanswered.

Bortel's Pegasus Investment Management did get into some hot water with the SEC in 2011, but it was over the erroneous classification of $90,000 in cash payments related to futures trades. The SEC's cease-and-desist order can be read here and has nothing at all to do with short selling or Ampio.

Dredly and Bortel are right to question the legitimacy of Ampio's drugs. I've done the same thing.

In April 2012, Ampio claimed to have reached agreement with regulatory officials in Australia that would allow the company to seek approval for Zertane in June 2012.

I warned investors to be wary of Ampio's misleading claims about Zertane.

June 2012 came and went without a follow-up announcement from Ampio about filing Zertane for approval in Australia. Instead, Ampio issued a press release conceding the company would be required to conduct two, phase III studies of Zertane before seeking approval in the U.S.

One year later, Ampio has still not submitted an approval application for Zertane in Australia, nor has the company started the two phase III studies required before it can seek approval in the U.S. Repeated promises by Ampio management to find a partner for Zertane have also gone unfulfilled.

Ampio spokesman Rick Giles, reached for comment via email Friday, didn't why the company has been unable to meet any of its Zertane timelines.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMPE $4.20 0.00%
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs